Perspective Therapeutics Inc. (CATX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Perspective Therapeutics Inc. stock (CATX) is currently trading at $4.29. Perspective Therapeutics Inc. PS ratio (Price-to-Sales) is 573.53. Analyst consensus price target for CATX is $13.20. WallStSmart rates CATX as Sell.
- CATX PE ratio analysis and historical PE chart
- CATX PS ratio (Price-to-Sales) history and trend
- CATX intrinsic value — DCF, Graham Number, EPV models
- CATX stock price prediction 2025 2026 2027 2028 2029 2030
- CATX fair value vs current price
- CATX insider transactions and insider buying
- Is CATX undervalued or overvalued?
- Perspective Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- CATX Piotroski F-Score and Altman Z-Score
- CATX analyst price target and Smart Rating
Perspective Therapeutics Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Perspective Therapeutics Inc. (CATX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Perspective Therapeutics Inc. (CATX) Key Strengths (1)
54.52% held by institutions, strong professional interest
Supporting Valuation Data
Perspective Therapeutics Inc. (CATX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -43.40%, a shrinking business
Very expensive at 573.5x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Perspective Therapeutics Inc. (CATX) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (573.53), Price/Book (2.45) suggest expensive pricing. Growth concerns include Revenue Growth at -43.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -41.60%, Operating Margin at -92633.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -41.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -43.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CATX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CATX's Price-to-Sales ratio of 573.53x trades 535% above its historical average of 90.34x (95th percentile), historically expensive. The current valuation is 54% below its historical high of 1255.12x set in Aug 2024, and 23502% above its historical low of 2.43x in Sep 2022.
WallStSmart Analysis Synopsis
Data-driven financial summary for Perspective Therapeutics Inc. (CATX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Perspective Therapeutics Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 884,000 with 43% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 27M in cash.
Spending 3724% of revenue (33M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 43% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -20M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.80, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Perspective Therapeutics Inc..
Bottom Line
Perspective Therapeutics Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Perspective Therapeutics Inc.(CATX)
NYSE MKT
HEALTHCARE
MEDICAL DEVICES
USA
Perspective Therapeutics Inc. is an innovative biotechnology company specializing in the development of next-generation radiopharmaceuticals designed to treat various types of cancer. Utilizing cutting-edge radioisotope technologies, the company aims to enhance the efficacy of cancer treatments, thereby improving patient outcomes in a rapidly evolving market for targeted therapies. With a strong leadership team and strategic partnerships, Perspective Therapeutics is well-equipped to advance its mission and deliver breakthrough solutions that address the growing need for effective cancer interventions.